HSP

Hospira Inc. (HSP) disclosed Friday that it recently received a warning letter from the Food and Drug Administration related to plants where it makes already-recalled dietary supplement and anesthesia products that had issues with metal particles.

The products in question are called Liposyn and Propofol, which Hospira voluntary pulled from the market in November. In a filing with the Securities and Exchange Commission late Friday, Hospira said the FDA letter covered two plants in North Carolina.

Warning letters can prove expensive and time-consuming to resolve, and can also put a hold on FDA approval for products related to the issues it found. Hospira said this letter doesn't restrict production or shipping at the North Carolina plants, but the company is holding shipment of certain products pending further investigation and discussion with the FDA.

Hospira shares slipped 1.7% in after-hours trading Friday to $56.11. Shares declined 1.2% during regular trading hours.

The Lake Forest, Ill., company also said it doesn't anticipate these matters will adversely affect its ability to achieve its 2010 financial projections, although it said future regulatory action from the FDA could have a material impact on results. The company said it takes the matter seriously and intends to respond fully to the agency.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024